This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias About VYNDAQEL

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasStudy DesignEfficacySafety ProfileDosingSupporting Resources Supporting ResourcesNICE RecommendationAvailability in Scotland2021 ESC Heart Failure GuidelinesRisk Minimisation MaterialContact usVideosMaterials

Click here for VYNDAQEL®▼ (tafamidis) Prescribing Information. 

About VYNDAQEL

VYNDAQEL stabilises TTR, the destabilisation of which causes ATTR amyloidosis1,2

Indication

VYNDAQEL 61 mg is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM)1

Amyloid light chain (AL) amyloidosis must be excluded before starting treatment with VYNDAQEL

ATTR-CM is a rare condition that is life-threatening, under-recognised and under- or mis-diagnosed3,4

Learn about the efficacy of VYNDAQEL in patients with ATTR-CM

 ATTR-ACT results Loading

The prognosis of patients with ATTR-CM worsens with continued amyloid deposits, therefore early diagnosis is key to improving patient outcomes3,6

VYNDAQEL stablises TTR, slowing dissociation to monomers1,7

See how VYNDAQEL works to treat ATTR-CM

ATTR-CM=transthyretin amyloid cardiomyopathy; TTR=transthyretin. 

Explore moreWe have a team ready to support you with any queries. 
Get in touch
Loading

Navigate the Suspect & Detect Pfizer promotional website to learn more about ATTR-CM and its diagnosis

 View the Suspect & Detect Pfizer website Loading

References:

VYNDAQEL 61 mg (tafamidis) Summary of Product Characteristics.Castano A, Narotsky D, Maurer MS. Expert Analysis. American College of Cardiology. October 14, 2015. Available at:
https://www.acc.org/Latest-in-Cardiology/Articles/2015/10/13/08/35/Emerging-Therapies-for-Transthyretin-Cardiac-Amyloidosis [Last accessed February 2024].Witteles EM, Bokhari S, Damy T, et al. JACC Heart Fail. 2019;7(8):709–716.Lane T, Fontana M, Martinez-Naharro A, et al. Circulation. 2019;140:16–26.Vieira M, Saraiva MJ. Biomol Concepts. 2014;5(1):45–54.Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Circulation. 2017;135(14):1357–1377.Bulawa CE, Connelly S, DeVit M, et al. Proc Natl Acad Sci U S A. 2012;109:9629–9634.
PP-VYN-GBR-1258. February 2024

Learn about the efficacy of VYNDAQEL in patients with ATTR-CM

 ATTR-ACT results Loading

View VYNDAQEL dosing information

 Dosing Loading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​